SpyGlass Pharma, Inc. SGP
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +22.12%
- 1 year
- +22.12%
- Open
- 32.21
- Prev close
- 32.51
- Mkt cap
- 1.08B
- Vol
- 94.15K
- Avg vol
- 101.69K
- EPS
- -2.51
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 31.75
- High
- 32.93
- Forward P/E
- -11.46
- Beta
- 0.00
- Short ratio
- 9.43
- Inst. own
- 94.68%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 27.11
- 200-d avg
- 24.32
- 1y target
- 44.00
News
-
1 week ago benzinga.com
HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates SpyGlass Pharma (NASDAQ:SGP) with a Buy and maintains $37 price target.
-
1 week ago benzinga.com
SpyGlass Pharma Announces Trial Results From Bimatoprost Drug Pad-IOL System In Participants With Mild-To-Moderate Open Angle Glaucoma Reduces Mean IOP By 37% Across All Three Dose Cohorts; 86% Participants Remained Off All Topical IOP-Lowering Drops
SpyGlass Pharma, Inc. (Nasdaq: SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye
1 week ago globenewswire.com
SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System
Groundbreaking 4-year safety and efficacy results: 37% reduction in mean intraocular pressure (IOP) across all dose groups 86% of patients remained off all topical IOP-lowering drops 90% of patients…
2 weeks ago businesswire.com
EdgeConneX Enters Australia in Partnership with Stockland, with Hyperscale Data Center Campuses Planned in Sydney and Melbourne
SYDNEY--(BUSINESS WIRE)--EdgeConneX®, a pioneer in global Build-to-Suit and Build-to-Density digital infrastructure solutions, today announced its entry into the Australian market through a 50-50…
-
3 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates SpyGlass Pharma (NASDAQ:SGP) with a Buy and maintains $37 price target.
-
1 month ago benzinga.com
SpyGlass Pharma Acquires Advanced Vision Science For ~$13M In Cash
SpyGlass Pharma acquires 100% of the outstanding shares of AVS, a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), the existing manufacturer of SpyGlass Pharma’s intraocular lens (IOL)Secures…
1 month ago globenewswire.com
SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
IRVINE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”) announced today the acquisition of all the outstanding shares of common stock of…
1 month ago seekingalpha.com
SpyGlass Pharma, Inc. (SGP) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
SpyGlass Pharma, Inc. (SGP) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
2 months ago globenewswire.com
SpyGlass Pharma to Participate in Upcoming Investor Conferences
IRVINE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the…
2 months ago benzinga.com
This Aehr Test Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday (CORRECTED)
Wall Street analysts changed ratings for top names. Visit our analyst ratings page for details. SGP initiated with Outperform, $39 PT.
2 months ago 247wallst.com
Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More
Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names like Wayfair, Roku, and Fox Corporation, while cooler inflation data reshuffled bets across stocks,…
-
2 months ago benzinga.com
Raymond James Initiates Coverage On SpyGlass Pharma with Outperform Rating, Announces Price Target of $39
Raymond James analyst Christopher Raymond initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Outperform rating and announces Price Target of $39.
2 months ago globenewswire.com
SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027. Bimatoprost-Drug Ring System…
3 months ago defenseworld.net
Spyglass Pharma (NASDAQ:SGP) Shares Gap Up – Still a Buy?
Spyglass Pharma, Inc. (NASDAQ: SGP - Get Free Report)'s stock price gapped up prior to trading on Friday. The stock had previously closed at $20.88, but opened at $21.80. Spyglass Pharma shares last…
3 months ago defenseworld.net
Affinity Asset Advisors LLC Buys Shares of 250,000 Spyglass Pharma, Inc. $SGP
Affinity Asset Advisors LLC purchased a new position in shares of Spyglass Pharma, Inc. (NASDAQ: SGP) during the undefined quarter, according to its most recent 13F filing with the Securities and…
4 months ago globenewswire.com
SpyGlass Pharma Appoints Shannon Treviño as General Counsel
ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of…
5 months ago globenewswire.com
SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
ALISO VIEJO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced the appointment of Mike Pinder as…
5 months ago globenewswire.com
SpyGlass Pharma to Participate in Upcoming Investor Conferences
ALISO VIEJO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the…
-
5 months ago benzinga.com
SpyGlass Says AMA CPT Editorial Panel Approves New Add-On Category III CPT Code For Attachment, Insertion Of Intraocular Lens Prosthesis-Mounted Drug-Eluting Implant
SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced that the American Medical Association's (AMA) CPT® (Current Procedural Terminology)…
5 months ago globenewswire.com
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
ALISO VIEJO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced that the American Medical…
-
5 months ago benzinga.com
SpyGlass Pharma Q1 EPS $(0.69) Misses $(0.42) Estimate
SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.42) by 64.29 percent. This is a 82.58 percent increase over losses of…
5 months ago globenewswire.com
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
ALISO VIEJO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business…
6 months ago defenseworld.net
Analyzing Longevity Health (NASDAQ:XAGE) and Spyglass Pharma (NASDAQ:SGP)
Spyglass Pharma (NASDAQ: SGP - Get Free Report) and Longevity Health (NASDAQ: XAGE - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the…
-
7 months ago benzinga.com
SpyGlass Pharma Q4 EPS $(5.72) Down From $(4.58) YoY
SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(5.72) per share. This is a 24.89 percent decrease over losses of $(4.58) per share from the same period last year.
7 months ago globenewswire.com
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
ALISO VIEJO, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business…
7 months ago defenseworld.net
Comparing Spyglass Pharma (NASDAQ:SGP) & Nanovibronix (NASDAQ:FEED)
Nanovibronix (NASDAQ: FEED - Get Free Report) and Spyglass Pharma (NASDAQ: SGP - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will contrast the…
7 months ago defenseworld.net
Longevity Health (NASDAQ:XAGE) and Spyglass Pharma (NASDAQ:SGP) Financial Comparison
Spyglass Pharma (NASDAQ: SGP - Get Free Report) and Longevity Health (NASDAQ: XAGE - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will contrast the…
-
7 months ago benzinga.com
HC Wainwright & Co. Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $37
HC Wainwright & Co. analyst Yi Chen initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy rating and announces Price Target of $37.
-
7 months ago benzinga.com
SpyGlass Pharma Announces Positive Topline 1/2 Trial Results For BIM-IOL Intracranial Pressure Treatment
12-month results from the Phase 1/2 trial evaluating its lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), for the treatment of elevated intraocular pressure (IOP) in…
7 months ago globenewswire.com
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
ALISO VIEJO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced positive 12-month results from…
8 months ago benzinga.com
This MongoDB Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Wall Street analysts changed ratings on top companies. See full list at benzinga.com/analyst-stock-ratings. MDB outlook downgraded to Neutral.
-
8 months ago benzinga.com
Citigroup Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $42
Citigroup analyst Yigal Nochomovitz initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy rating and announces Price Target of $42.
-
8 months ago benzinga.com
Leerink Partners Initiates Coverage On SpyGlass Pharma with Outperform Rating, Announces Price Target of $42
Leerink Partners analyst Marc Goodman initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Outperform rating and announces Price Target of $42.
-
8 months ago benzinga.com
Jefferies Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $62
Jefferies analyst Dennis Ding initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy rating and announces Price Target of $62.
8 months ago benzinga.com
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
Top Wall Street analysts changed outlook on top names. Check out analyst ratings page for all changes. AMLX, OFRM, AGMB, SGP initiated with positive outlook.
-
8 months ago benzinga.com
Stifel Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $42
Stifel analyst Tom Stephan initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy rating and announces Price Target of $42.
8 months ago benzinga.com
Spyglass Pharma, Inc To Start Trading Tomorrow
Spyglass Pharma, Inc To Start Trading Tomorrow
-
15 years ago benzinga.com
Assistant Secretary for International Finance Charles Collyns Written Testimony before the House Committee on Financial Services Subcommittee on International Monetary Policy and Trade
Assistant Secretary for International Finance Charles Collyns Written Testimony before the House Committee on Financial Services Subcommittee on International Monetary Policy and Trade
-
15 years ago benzinga.com
UPDATE: ISI Group Initiates Coverage on NetApp at Buy, $48 PT
UPDATE: ISI Group Initiates Coverage on NetApp at Buy, $48 PT
-
16 years ago benzinga.com
Time Warner Director Buys $1 Million Worth Of Shares (TWX, SGP)
Time Warner Director Buys $1 Million Worth Of Shares (TWX, SGP)
-
16 years ago benzinga.com
The World's Largest M&A Deals in 2009 (PFE, WLA, GM, SGP, MRK)
The World's Largest M&A Deals in 2009 (PFE, WLA, GM, SGP, MRK)
-
17 years ago benzinga.com
Priceline.com Added To The S&P 500, Replacing Schering-Plough
Priceline.com Added To The S&P 500, Replacing Schering-Plough
-
17 years ago benzinga.com
European Commission Approves Schering-Plough (SGP) and Centocor's Simponi Drug
European Commission Approves Schering-Plough (SGP) and Centocor's Simponi Drug
-
17 years ago benzinga.com
US Court Rejects the Attempt by Schering-Plough's (SGP) to Repatriate $690M without Taxes
US Court Rejects the Attempt by Schering-Plough's (SGP) to Repatriate $690M without Taxes
-
17 years ago benzinga.com
SGP Reports Second Quarter 2009 Results
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 14, 2009) - NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS…